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The fumagillin family of natural products is known to
inhibit angiogenesis through irreversible inhibition of
human type 2 methionine aminopeptidase (MetAP2).
Recently, fumagillin and TNP-470 were reported to
possess antimalarial activity in vitro, and it was
hypothesized that this inhibition was mediated by
interaction with the putative malarial ortholog of
humanMetAP2. In this report,wehaveoverexpressed
and purified to near-homogeneity PfMetAP2 from
bacteria, yeast, and insect cells. Although none of
the recombinant forms of PfMetAP2 exhibited enzy-
matic activity in existing assays, PfMetAP2 proteins
expressed in both yeast and insect cells were able
to bind to fumagillin in a pull-downassay. The interac-
tion between fumagillin and analogs with PfMetAP2
was further demonstrated using a newly established
mammalian three-hybrid assay incorporatinga conju-
gate between dexamethasone and fumagillin. Unlike
human (Hs)MetAP2, it was found that PfMetAP2
is bound to fumagillin noncovalently. Importantly, a
new analog of fumagillin, fumarranol, was demon-
strated to interact with PfMetAP2 and inhibit the
growth of both chloroquine-sensitive and drug-resis-
tant Plasmodium falciparum strains in vitro. Antipara-
site activity of fumagillin and fumarranol was also
demonstrated in vivo using a mouse malaria model.
These findings suggest that PfMetAP2 is a viable
target, and fumarranol is a promising lead compound
for the development of novel antimalarial agents.
INTRODUCTION
Cleavage of N-terminalmethionine of newly synthesized proteins
is an essential cotranslational modification process that is
required for proper subcellular localization, folding, and activities
for a large subset of cellular proteins (Boutin, 1997; Hu et al.,
2007;Perrier et al., 2005; Varshavsky, 1996). Thisprocess is cata-
lyzed by a family of highly conserved enzymes known as methio-Chemistry & Biology 16, 193nine aminopeptidases (MetAPs). There are two types of MetAPs:
type 1 (MetAP1) and type 2 (MetAP2), which differ by the pres-
ence of a unique insertion of about 60 amino acids toward the
C terminus of the catalytic domain in MetAP2. The prototypical
MetAP1 and MetAP2 from prokaryotic bacteria and archaea
contain the minimal catalytic domain. In contrast, eukaryotic
MetAPs possess additional N-terminal domains. Thus, eukary-
otic MetAP1 contains an N-terminal zinc finger motif that was
shown to be involved in association with the ribosome in yeast
(Vetro and Chang, 2002). Eukaryotic MetAP2 possesses an
N-terminal poly-basic and acidic repeats that were shown to
inhibit phosphorylation of eukaryotic initiation factor 2a subunit
and enhance the rate of global protein synthesis (Datta et al.,
1989, 2001, 2003a, 2003b, 2006, 2007; Ghosh et al., 2006).
Several lines of evidence suggest that MetAP1 is constitutively
expressed and is more likely to be a housekeeping enzyme,
whereasMetAP2 expression is subject to regulation by cell cycle
status and other extracellular signals (Chatterjee et al., 1998;
Gupta et al., 1997). The importance of this family of enzymes is
underscored by the lethal phenotypes of knockouts in both
bacteria and yeast (Chang et al., 1989; Li and Chang, 1995).
Given their critical roles in cell viability in bacteria and lower
eukaryotes, MetAPs have become attractive targets for devel-
oping drugs against bacteria and other pathological organisms.
Considerable efforts have been made by many laboratories
including ours to search for selectiveMetAP inhibitors for various
pathologic organisms such as Escherichia coli, Staphylococcus
aureus,Encephalitozoon intestinalis, andPlasmodium falciparum
(Chen et al., 2006; Didier, 1997; Huang et al., 2007; Oefner et al.,
2003). In multicellular eukaryotic organisms, different isoforms of
MetAP enzymes appear to have diverged in their functions and
evolved tissue- and cell type-specific functions. For example,
MetAP2was identified asa relevant target for the fumagillin family
of antiangiogenic natural products and was subsequently shown
to play an important role in endothelial cell proliferation and
angiogenesis (Griffith et al., 1997; Sin et al., 1997). More recently,
human MetAP1 was shown to be involved in the control of cell
cycle progression in the G2/M phase (Hu et al., 2006).
Malaria causes1 to 2million deathseach year in thedeveloping
world, with most mortality occurring among children. The emer-
gence and rapid spread of drug resistance to existing antimalarial
drugs such as chloroquine has posed a significant challenge to
controlling the disease. There is an urgent need to develop new–202, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 193
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tance to existing drugs. Chiang and colleagues first reported
that fumagillin and its synthetic analog TNP-470 are potent
inhibitors of malaria parasite growth in cell culture, raising the
possibility that fumagillin and analogs may be exploited as
novel antimalarial agents (Zhang et al., 2002). Although malaria
P. falciparum MetAP2 (PfMetAP2) was suggested as the likely
target, therewas no direct evidence in support of the proposition.
In addition, a BLAST search of the P. falciparum (3D7) genome
revealed an ortholog of HsMetAP2, PfMetAP2 (GeneDB acces-
sion number PF14_0327), whose protein sequence is longer
than the one reported earlier (Zhang et al., 2002). As shown in
Figure 1, there are 274 additional amino acids at the N terminus
(1MNK-CIPID274), although the five amino acids (2 Asp, 1 His,
and 2 Glu) responsible for metal coordination at the active site
of all known MetAP enzymes are all conserved in PfMetAP2
(highlighted as white on a black background). These observa-
tions left open the question of whether the putative PfMetAP2
protein is a physiologically relevant target for fumagillin and
TNP-470.
While TNP-470 reachedPhased II clinical trials for cancer treat-
ment, its dose-limiting neurotoxicity and extremely short half-life
in vivo prevented its further advancement (Bhargava et al., 1999;
Kruger and Figg, 2000). In attempts to reduce the toxicity and
improve the pharmacological activities of the fumagillin-based
MetAP2 inhibitors, we and others have synthesized and tested
several analogs of fumagillin. Among the new fumagillin analogs
reported to date, one stood out for its distinct structure and ability
to reversibly associate with HsMetAP2 and lower toxicity in
animals. It is known as fumarranol due to its rearranged core
structure derived from the fumagillin backbone. In contrast to
TNP-470 and the majority of known analogs of fumagillin, fumar-
ranol is a noncovalent inhibitor of HsMetAP2 (Lu et al., 2006).
Despite its reduced potency against HsMetAP2 (IC50 = 3 mM), it
Figure 1. The Deduced PfMetAP2 Protein
Sequence Shares High Identity to HsMetAP2
Protein sequence alignment using the Clustalw2
program (www.ebi.ac.uk/Tools). Red (AVFPMILW)
indicates small amino acids (small + hydrophobic
[including aromatic Y]), blue (DE) indicates
acidic, magenta (RK) indicates basic, and green
(STYHCNGQ) indicates hydroxyl + amine +
basic  Q. An asterisk (*) means that the residues
in that column are identical, a colon (:) indicates
conserved substitutions, and a period (.) indicates
semiconserved substitutions. The human Histi-
dine 231 (His231) and malaria His380 appear in
white on a gray background. The five amino acids
responsible for metal coordination appear in white
on a black background.
is quite active in an endothelial cell prolif-
eration assay, with an IC50 of 34 nM (Lu
et al., 2006). Significantly, a 10-day treat-
ment with fumarranol at 90 mg/kg/day
showed an antiangiogenesis potency
comparable to TNP-470 at 30 mg/kg/day
in a mouse angiogenesis model. More-
over, treatment of fumarranol did not
cause the skin lesions that were seen in the TNP-470 group.
The knownantimalarial activity of fumagillin andTNP-470promp-
ted us to determine whether fumarranol also possesses antima-
larial activity, and if so, whether it works through inhibition of
PfMetAP2.
We herein disclose our findings on the expression, purification,
and characterization of PfMetAP2 as well as its interaction with
fumagillin and analogs. It was shown that recombinant PfMetAP2
from both E. coli and yeast are inactive in the MetAP enzymatic
assay using an oligopeptide substrate in vitro. Using a biotin-
fumagillin conjugate, however, we were able to pull down re-
combinant PfMetAP2 expressed in yeast, demonstrating their
direct interaction. This interaction was further confirmed in
a mammalian three-hybrid system in cells. We also found that
fumarranol binds to PfMetAP2 and inhibits malaria growth
in vitro. AnSARstudywith fumarranol analogs revealed a correla-
tion between binding affinities for PfMetAP2 and inhibition of
malaria growth in culture. Importantly, fumarranol was also found
to inhibit growth of malaria parasite in vivo in a rodent malaria
model.
RESULTS
The Deduced PfMetAP2 Protein Sequence Shared High
Sequence Identity with HsMetAP2
The C-terminal catalytic domain of PfMetAP2 (265-628) and
HsMetAP2 (112-478) share 58% sequence identity. The charac-
teristic 64-amino acid insertion in HsMetAP2 (highlighted in bold
and black) is highly conserved in PfMetAP2. HsMetAP2 contains
one acidic domain (77EDKERDEDDEDGDGDGDG94, in blue) and
two basic domains (36KKKRRKKKK44 and 98KKKKKKKKKR107
in magenta) at its N-terminal extension (Figure 1). These three
charged domains were also conserved in PfMetAP2. Unlike
HsMetAP2, however, the N-terminal noncatalytic domain of194 Chemistry & Biology 16, 193–202, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
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are characteristic of malarial proteins. Differences in amino acids
are also found throughout the catalytic domain between
PfMetAP2 and HsMetAP2. In particular, residue K501 of
PfMetAP2 was absent in HsMetAP2, likely leading to significant
difference in the active sites between the two enzymes.
Biotin-Fum Binds Recombinant PfMetAP2
Overexpressed and Purified from Yeast
but Not from E. coli
HsMetAP2, also known as p67, was reported to contain glyco-
sylation sites (Datta et al., 2001, 2003a, 2007). The recombinant
HsMetAP2 overexpressed and purified from E. coli lacked
glycosylation with an apparent molecular weight of 53 kDa on
SDS-PAGE and was found to be inactive. In contrast, recombi-
nant HsMetAP2 overexpressed and purified from insect cells
was active, with an apparent molecular weight of approximately
71 kDa (with a 4-kDa 6xHis tag) on SDS-PAGE (Griffith et al.,
1998; Li and Chang, 1996). Similarly, PfMetAP2 overexpressed
in E. coli had an apparent molecular weight of 72 kDa, whereas
PfMetAP2 overexpressed in yeast was approximately 90 kDa
(containing a 4-kDa Xpress epitope and 6xHis tag) (Figure 2A).
To determine whether fumagillin (Figure 2B) can bind to re-
combinant PfMetAP2, a biotinylated fumagillin (biotin-Fum)
(Figure 2B) was used in a pull-down assay with HsMetAP2 as
a positive control (Griffith et al., 1997). Whereas biotin alone
could not pull down either HsMetAP2 or PfMetAP2-Sc, biotin-
Fum dose-dependently pulled down both HsMetAP2 and
PfMetAP2-Sc. The relative binding affinity of biotin-Fum for
PfMetAP2-Sc was approximately 50-fold weaker than that for
HsMetAP2 judging from the minimal concentrations of biotin-
Fum that were required to detect each enzyme (Figure 2C). In
contrast, biotin-Fum failed to pull down PfMetAP2-Ec even at
100 mM.
Figure 2. Biotin-Fum Binds to PfMetAP2-Sc
but Not PfMetAP2-Ec
(A) Purified PfMetAP2-Ec (from E. coli) and
PfMetAP2-Sc (from yeast) was detected on
westernblot analysis using anti-His-HRPantibody.
(B) Structures of fumagillin and biotin-Fum.
(C) Biotin-Fum but not biotin dose-dependently
bound toHsMetAP2-Ic (from insect cell) andPfMe-
tAP2-Sc with different affinity. Biotin-Fum up to
100 mM did not bind to PfMetAP2-Ec.
The Binding of Biotin-Fum
to Recombinant PfMetAP2-Sc
Is Noncovalent
Fumagillin and TNP-470 have been
shown to bind to HsMetAP2 covalently
(Griffith et al., 1997; Sin et al., 1997). The
covalent interaction between fumagillin
or biotin-Fum conjugate and HsMetAP2
can withstand denaturation conditions in
SDS-PAGE gel loading buffer in boiling
water, enabling detection using a near-
western blot assay (Griffith et al., 1997).
To determine whether the binding of
biotin-Fum to PfMetAP2 is also covalent, the PfMetAP2-Sc
was incubated with biotin-Fum for 2 hr and the mixture was
then heated in boiling water for 10 min before SDS-PAGE fol-
lowed by near-western blot assay. As shown in Figure 3A, while
the binding of biotin-Fum to the HsMetAP2 was covalent, the
binding to PfMetAP2-Sc was not. No biotin signal could be
detected from PfMetAP2-Sc samples with up to 100 mM biotin-
Fum (Figure 3A). The reversible interaction between PfMetAP2
and fumagillin was also verified by examining the stability of
the complex between biotin-fum and PfMetAP2 upon dialysis.
The remaining complex between biotin-Fum and MetAP2 was
captured with streptavidin beads and detected using antibodies
against the 6XHis tag in a western blot. As shown in Figure 3B,
while the complex between biotin-Fum andHsMetAP2 remained
intact during dialysis, the PfMetAP2 complex with biotin-Fum
could no longer be detected, consistent with the noncovalent
and reversible binding of biotin-Fum to PfMetAP2.
Verification of the Interaction Between Fumagillin
and PfMetAP2 Using the Mammalian Three-Hybrid
System In Vivo
For reasons that remain unknown, PfMetAP2 expressed and
purified from yeast or insect cells was not active in enzymatic
assay (data not shown). To facilitate SAR studies, we decided
to establish a mammalian three-hybrid system that is based on
a yeast three-hybrid system (Licitra and Liu, 1996). The hybrid
ligand in this system is a heterodimer between fumagillin (Fum)
and dexamethasone (Dex). To ensure that the Dex-Fum hetero-
dimer retained its ability to interact with PfMetAP2, one hetero-
dimer, Fum-12O2-Dex4 (Figure 4A) was tested as a competitor
in a biotin-Fum mediated pull-down assay using recombinant
PfMetAP2 purified from yeast. PfMetAP2-Sc was thus incubated
with various concentrations of Fum-12O2-Dex4 for 2 hr before
biotin-Fum was added to capture free PfMetAP2. As shown inChemistry & Biology 16, 193–202, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 195
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lent to PfMetAP2-Sc
MetAP2 was incubated with different concentrations of
biotin-Fum for 2 hr.
(A) SDS loading buffer was added to the mixture with
10 min of boiling. The sample was subjected to SDS-
PAGE and detected for biotin signal with strep-hrp fol-
lowed by anti-6xHis antibody to check the loading, or (B)
the mixture was dialyzed against the binding buffer over-
night at 4Cbefore the 2-hr capture by streptavidin sephar-
ose beads. The MetAP2 on the beads was detected on
western blot analysis using anti-His-HRP antibody.Figure 4B, the preincubation with Fum-12O2-Dex4, but not Dex
alone, competed for the binding of PfMetAP2 to biotin-Fum in
a dose-dependent manner. This indicated that tethering of the
linker and dexamethasone in Fum-12O2-Dex4 did not affect
the ability of the fumagillin moiety of the heterodimer to interact
with PfMetAP2 in vitro.
We made two constructs, pVP16-PfMetAP2 and pM-rGRHBD
(524-796) (Chen et al., 2006), and cotransfected them into 293T
cells. If Fum-12O2-Dex4 could bind to both VP16AD-PfMetAP2
and Gal4DBD-rGRHBD(524-796), the VP16AD (transactivation
domain) and the Gal4DBD (DNA-binding domain) would be
brought together, causing expression of Gal4-DNA binding site-
driven luciferase reporter gene. Indeed, Fum-12O2-Dex4 was
able to activate the expression of the luciferase reporter gene
(Figure 5B). The biphasic bell-shaped dose-response curve re-
vealed an optimal activating concentration of the Dex-Fum dimer
at 0.3 mM. This is expected, because upon saturation of the two
hybrid proteins, VP16AD-PfMetAP2 and Gal4DBD-rGRHBD,
further increase in the concentration of Dex-Fum will lead to self-
competition between the free Fum-Dex heterodimer and those
present in the transcriptionally active VP16AD-PfMetAP2/Dex-
Fum/Gal4DBD-rGRHBD ternary complex and dissociation of the
ternary complex into transcriptionally inactive dimeric complex
between Dex-Fum and either of the hybrid protein receptors.
The ability of the Dex-Fum heterodimer to activate transcription
of the reporter gene suggests that Dex-Fum binds to PfMetAP2196 Chemistry & Biology 16, 193–202, February 27, 2009 ª2009 Elsin vivo in mammalian cells, providing further support to the notion
that fumagillin and analogs can directly bind to PfMetAP2.
Fumarranol Interacted with PfMetAP2 In Vivo
To determine whether fumarranol (Figure 5B) could bind to
PfMetAP2, we performed the Dex-Fum-mediated mammalian
three-hybrid assay in the absence and the presence of fumarra-
nol. Thus, 24 hr after cotransfection with the three-hybrid plas-
mids, 293T cells were treated with different concentrations of
potential competitors, including fumarranol for 4 hr, followed
by a 48-hr incubation with 0.3 mM Fum-12O2-Dex4. As previ-
ously shown (Chen et al., 2006), TNP-470 inhibited the luciferase
reporter gene activation (Figure 5C). Similarly, fumarranol also
inhibited the induction of luciferase by the Dex-Fum heterodimer
in a dose-dependent manner. The IC50 for fumarranol was esti-
mated to be 116 mM in comparison to 2 mM for TNP-470 (Table 1).
The ability of fumarranol to compete against Dex-Fum in this
assay clearly suggests that, like fumagillin and Dex-Fum, it is
also capable of binding to PfMetAP2. The roughly 58-fold lower
potency of fumarranol than that of TNP-470 in this competition
assay corroborates with its lower potency in parasite prolifera-
tion assay in comparison with TNP-470. In addition to fumarra-
nol, we also determined the IC50 values of other fumarranol
analogs in this competition assay. They are all above 500 mM,
consistent with their lower potency against malaria parasites
than fumarranol (Table 1).Figure 4. Fum-12O2-Dex4 but not Dex
Dose-Dependently Competed the Binding
of Biotin-Fum (25 mM) to PfMetAP2-Sc
(A) Structure of Fum-12O2-Dex4.
(B) PfMetAP2-Sc was incubated with different
concentrations of Fum-12O2-Dex4 or Dex for
2 hr before addition of biotin-Fum to capture all
the free PfMetAP2-Sc. All PfMetAP2-Sc bound to
biotin-Fum were captured by streptavidin beads
and detected by anti-6xHis antibody on western
blot analysis.evier Ltd All rights reserved
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Drug-Sensitive and Drug-Resistant P. falciparum
Parasites in Culture
We determined the effect of fumarranol on the growth of both
NF54 (drug-sensitive) and W2 (multidrug-resistant) strains. Fu-
marranol was found to be active in blocking the proliferation of
both strains with IC50 values of 0.16 and 0.27 mM, respectively
(Table 1). In comparison with TNP-470, the potency of fumarra-
nol is 80- to 100-fold lower. We also tested other fumarranol
analogs in the malaria parasite proliferation assay. None of the
analogs exhibited higher activity than fumarranol itself.
Fumarranol Cured Mice Infected with Chloroquine
Resistant P. yoelii Parasites
Fumarranol was further tested for its anti-malaria activity in vivo.
Mice were given fumarranol once a day for 4 days starting 1 hour
after infection with P. yoelii 17X lethal strain (chloroquine resis-
tant). Fumarranol at 60 and 120 mg/kg significantly inhibited the
parasitemia level on day 4 (Figure 6A). Fumarranol at 60 mg/kg
had a potency comparable to TNP-470 at 20 mg/kg. As
expected, chloroquine failed to completely eradicate the parasi-
temia at a dosage of 10 mg/kg, which indicated the existence of
chloroquine resistance of the P. yoelii strain. After the 4-day drug
treatment, mice were kept for another 26 days to determine the
mean survival time. All survivingmice were checked for parasite-
mia again to determine whether the parasites were completely
cleared. Only those mice without detectable parasitemia at day
30 after infection were considered cured. As shown in Figure 6B,
fumarranol extended themean survival time in adose-dependent
manner. At 120 mg/kg, fumarranol was more efficacious than
either TNP-470 at 20mg/kg or chloroquine at 10mg/kg.Whereas
only one mouse survived on day 30 in the 60 mg/kg fumarranol
group and the 20 mg/kg TNP-470 group, 2 and 3 mice survived
Figure 5. Fumarranol Could Inhibit Fum-
12O2-Dex4-Activated Expression of Lucif-
erase in a Mammalian Three-Hybrid System
(A) Structures of TNP-470 and fumarranol.
(B) Setup of the mammalian three-hybrid system.
Dose response of Fum-12O2-Dex4 in inducting
the activation of luciferase reporter gene in 293T
cells cotransformed with pVP16-PfMetAP2 and
pM-rGRHBD(524-796).
(C) Dose-dependent competition effect of TNP-
470 and fumarranol on the activation of luciferase
reporter gene by 0.3 mM Fum-12O2-Dex4. Data
are expressed as the mean ± SD.
in the chloroquine (10 mg/kg) group and
fumarranol (120 mg/kg) group, respec-
tively. In addition, two mice from the
120 mg/kg fumarranol-treatment group
were cured, whereas all other surviving
mice still had parasitemia between 0.1%
and 5% on day 30. Meanwhile, no skin
lesion or abnormal behavioral patterns
(e.g., fatigue, stress, or aggressiveness)
were observed among the mice with fumarranol treatment, indi-
cating that fumarranol is well tolerated by the mice.
DISCUSSION
In a previous study, an open reading frame was identified from
the P. falciparum genome that showed high sequence identity
with MetAP2 proteins from other eukaryotic organisms (Zhang
et al., 2002),whichwas assigned as the putativemalarial ortholog
of human MetAP2. It was hypothesized that the antimalarial
activity of fumagillin and TNP-470 is mediated by inhibition of
the PfMetAP2 enzyme. One unusual feature of the previously
identifiedPfMetAP2protein is that it lacked the uniqueN-terminal
extension of all other eukaryotic MetAP2 proteins, which contain
the domains rich in acidic or basic amino acids (Zhang et al.,
2002). It had appeared that malaria might have lost the unique
N-terminal extension during evolution. A careful search in the
P. falciparum database, however, revealed that the PfMetAP2
gene does encode an N-terminal extension beyond the core
catalytic domain. Similar to other eukaryotic MetAP2 proteins,
PfMetAP2 also contains stretches of poly-acidic and poly-basic
residues. Unlike MetAP2 proteins from other organisms, PfMe-
tAP2 contains poly-asparagine sequences within the N-terminal
domain, characteristic of other malarial proteins (Barale et al.,
1997; Bastien et al., 2004).
Although it has been shown previously that fumagillin and
TNP-470 both possess potent inhibitory effects on malaria
growth in vitro, and it has been speculated that PfMetAP2 is
a likely target, no experimental evidence exists to support this
hypothesis. In this study, we attempted to overexpress and purify
PfMetAP2 in a heterologous expression system and assess the
interaction between fumagillin and recombinant PfMetAP2.
Similar to human MetAP2, PfMetAP2 expressed and purifiedChemistry & Biology 16, 193–202, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 197
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Fumagillin and Fumarranol Inhibit Malaria GrowthTable 1. Affinity Assay of Fumarranol Analogs with PfMetAP2 using Mammalian Three-Hybrid System and the Effect of Fumarranol
Analogs on PfMetAP1a/b/c Enzymatic Activity and Proliferation of P. falciparum NF54 and W2 Strains In Vitro
Compound
IC50 (mM)
PfMetAP2 PfMetAP1a/b/ca NF54 W2
4 TNP-470 2.0 ± 1.0 >300a 0.002 ± 0.0003 0.003 ± 0.0003
5 Fumarranol 116 ± 27 >300a 0.16 ± 0.03 0.27 ± 0.07
6 >500 ND 6.3 ± 1 8.8 ± 0.9
7 >500 ND 1.6 ± 0.5 1.6 ± 0.5
8 >500 ND 71 ± 7 >100
9 >500 ND >100 >100
10 >500 ND >100 >100
Data are expressed as the mean ± SD.
ND, not determined.
a Due to the limitation of solubility in the enzyme assay for PfMetAP1a/b/c, only up to 300 mM of the above compounds were tested.from bacteria is inactive, perhaps due to lack of the appropriate
posttranslational modifications in bacteria hosts (Baneyx and
Mujacic, 2004). Whereas HsMetAP2 expressed in baculovirus-
driven insect cells is fully active as an enzyme and binds fumagil-
lin, PfMetAP2 expressed and purified from insect cells did not
exhibit any enzymatic activity using a variety of N-terminal methi-
onine-containing oligopeptide substrates (data not shown). It is
possible that PfMetAP2 undergoes unique posttranslational
modifications that cannot be recapitulated in insect cells or yeast.
It is also possible that PfMetAP2 acts on a unique substrates
within malarial parasites yet to be identified.198 Chemistry & Biology 16, 193–202, February 27, 2009 ª2009 ElseDespite the lack of enzymatic activity, the recombinant
PfMetAP2 purified from either yeast or insect cells was able to
bind to fumagillin as demonstrated by the pull-down assay using
biotin-Fum. To further verify the interaction between fumagillin
and PfMetAP2, we turned to a mammalian three-hybrid system
that can be used to detect small molecule-protein interaction
in mammalian cells. One advantage of the mammalian three-
hybrid assay is that PfMetAP2 fusion protein is expressed in
a mammalian host cells, allowing for the possible posttransla-
tional modification. Another advantage of the mammalian
three-hybrid system is that the signal in the form of activationvier Ltd All rights reserved
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nol in Mouse Model
(A) Effect of subcutaneously administered fumar-
ranol on parasitemia. C57BL/6 mice infected
with P. yoelii 173 lethal strain were given fumarra-
nol (FMR 20, 60, or 120 mg/kg) or TNP-470 (TNP
20 mg/kg) or chloroquine (CQ 10 mg/kg) or equal
volume of vehicle (control) once a day for 4 days.
**p < 0.01 versus control.
(B) Effect of subcutaneously administered fumar-
ranol on time of survival. - = control. B = FMR
20 mg/kg. , = FMR 60 mg/kg. 6 = FMR
120mg/kg.3 = TNP 20mg/kg.C = CQ 10mg/kg.
n = 5 in all groups. Data are expressed as the
mean ± SD.of a reporter gene is solely dependent on the interaction between
PfMetAP2 and the fumagillin portion of the three-hybrid ligand,
Dex-Fum conjugate. That the Dex-Fum conjugate is active
both in competing against biotin-Fum for recombinant PfMetAP2
protein in vitro and activating the three-hybrid reporter gene in
cells due in part to the direct binding of Dex-Fum to PfMetAP2
fusion protein provides strong support for the notion that fuma-
gillin is capable of binding to PfMetAP2. TNP-470 and fumarranol
were able to compete against Dex-Fum to block the reporter
gene activation with potencies in line with their relative activity
against malaria growth in vitro. The same was seen with
a number of less active fumarranol analogs. The correlation
between the ability to compete for PfMetAP2 binding in the
mammalian three-hybrid system and to inhibit malaria growth
in vitro is consistent with PfMetAP2 as a potential target for
fumagillin, fumarranol, and their analogs. Additional genetic
evidence, including genetic knockout of PfMetAP2, will be
required to fully validate PfMetAP2 as the target for fumagillin
and fumarranol.
Fumagillin and analogs were known to bind to human and
yeast MetAP2 covalently through the modification of His231 in
the active site of the enzyme (Griffith et al., 1998; Liu et al.,
1998). This can be detected using the near-Western blot analysis
with the help of biotin-Fum (Griffith et al., 1997). In contrast to
HsMetAP2, the recombinant PfMetAP2 expressed in insect cells
or yeast appeared to bind to fumagillin reversibly (Figure 3). It is
noteworthy that the same His residue modified by fumagillin in
human MetAP2 is conserved in PfMetAP2 (His380). Thus, the
inability of fumagillin to covalently modify His380 in PfMetAP2
may likely be attributed to other residues in the active site of
PfMetAP2 that differ from their counterpart of HsMetAP2. In
addition, the insertion of a single residue, K501, in the catalytic
domain of PfMetAP2, which is absent in HsMetAP2, could also
render the structure of the active site of PfMetAP2 significantly
different from that of HsMetAP2. It is thus likely that fumagillin
is accommodated in the active site of PfMetAP2 in such a way
that the spiro epoxide group can no longer reach the imidazole
side chain of His380, as it does with HsMetAP2.
There are four different MetAP isoforms in P. falciparum:
PfMetAP1a, PfMetAP1b, PfMetAP1c, and PfMetAP2.
PfMetAP1a, PfMetAP1b, and PfMetAP1c all belong to the type
1 MetAP family. PfMetAP1b has an N-terminal domain bearing
two zinc finger motifs that are absent from PfMetAP1a andChemistry & Biology 16, 193PfMetAP1c. Whereas PfMetAP1a contains a minimal catalytic
domain, PfMetAP1c has a long N-terminal domain that was
predicted to contain a signal peptide for targeting PfMetAP1c
into the apicoplast. All three type 1 PfMetAPs have been overex-
pressed andpurified fromE. coli andhavebeen found to be enzy-
matically active (Chen et al., 2006). We thus tested TNP-470 and
fumarranol against each of the three type 1 PfMetAPs using the
coupledMetAP enzymatic assay (Chen et al., 2006). At a concen-
tration of 300 mM, neither TNP-470 nor fumarranol affected the
activity of PfMetAP1a, PfMetAP1b, or PfMetAP1c (Table 1), sug-
gesting that TNP-470 aswell as fumarranol are specific inhibitors
of PfMetAP2 andbolstering the notion that inhibition of PfMetAP2
is likely the cause of inhibition of malarial growth.
Similar to TNP-470, the rearranged fumagillin analog fumarra-
nol was found to be effective against both wild-type (clone NF54)
and multidrug-resistant (W2) P. falciparum strains with roughly
equal potency (Table 1). In comparison with TNP-470, fumarra-
nol was about 80 fold less potent. This is consistent with the
lower binding affinity of fumarranol for PfMetAP2 observed in
the mammalian three-hybrid assay. To compare their potency
in vivo, fumarranol and TNP-470 were tested in mice infected
with Plasmodium yoelii 17X lethal strain (chloroquine resistant).
As expected, at the same dose of 20 mg/kg, fumarranol was
less effective than TNP-470 (Figure 6). However, an increase in
fumarranol dose to 120 mg/kg yielded a better outcome than
TNP-470 at 20 mg/kg or chloroquine at 10 mg/kg. Furthermore,
three out five mice survived after 120 mg/kg fumarranol treat-
ment, two of which were completely cured (free of parasites).
Given that fumarranol exhibited much lower toxicity than TNP-
470, these data suggest that fumarranol or its more potent
analogs may be promising leads for developing antimalarial
agents.
SIGNIFICANCE
The human MetAP2 has been shown to be the target for the
fumagillin family of antiangiogenic natural products. Recent
evidence suggests that fumagillin and its analog TNP-470
also possess potent antimalarial activity in vitro, likely
through the inhibition of the malarial ortholog of HsMetAP2,
PfMetAP2. However, there has been no direct experimental
evidence supporting this hypothesis. Moreover, TNP-470
failed in human clinical trials due to its undesirable–202, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 199
Chemistry & Biology
Fumagillin and Fumarranol Inhibit Malaria Growthpharmacological profiles, including short serumhalf-life and
dose-limiting neurotoxicity, necessitating the identification
of new inhibitors of PfMetAP2 as a lead. In this manuscript,
we provide direct experimental evidence for the interaction
between TNP-470 and PfMetAP2 by obtaining recombinant
PfMetAP2 from yeast and insect cells. We demonstrate
that unlike HsMetAP2, PfMetAP2 is bound to fumagillin in
a reversible manner despite the conservation of an active
site histidine residue that is known to be covalently modified
by fumagillin and TNP-470, underscoring the difference in
the active sites between HsMetAP2 and PfMetAP2. We
show for the first time that TNP-470 is active in blocking
malaria growth in vivo. We also found that fumarranol, an
analog of fumagillin, retained both isoform specificity and
the ability to inhibit malaria growth in vitro and in vivo.
Together, these findings suggest that PfMetAP2 is a viable
new target and fumarranol is a promising lead for developing
new antimalarial agents.
EXPERIMENTAL PROCEDURES
Materials
All chemical reagents used in organic synthesis were purchased from Aldrich
(St. Louis, MO). Biotin and dexamethasone were from Sigma (St. Louis, MO).
Syntheses of biotin-labeled fumagillin (compound 1), TNP-470 (compound 3),
fumarranol, and its derivatives (compound 4 to 9) were performed as described
previously (Griffith et al., 1997; Lu et al., 2006). The Fum-Dex dimmer was
synthesized using a previously reported procedure (Licitra and Liu, 1996).
Each compound was confirmed by 1H-NMR, 13C-NMR, and mass spectrom-
etry. The details are reported in the Supplemental Material.
The vector pYES2/NTcand thehost yeast strain INVSc1were from Invitrogen
(Carlsbad, CA). The vector pET29a and the host E. coli BL21 were from Nova-
gen (San Diego, CA). The vectors pM and pVP16 for the mammalian three-
hybrid system were from Clontech (Mountain View, CA). Construction of
plasmids pVP16-PfMetAP2 and pM-rGRHBD (524-796) encoding vp16AD-
PfMetAP2 and Gal4DBD-rGRHBD(524-796), the wild-type hormone-binding
domain of rat glucocorticoid receptor (524-796), has been described (Chen
et al., 2006).
Overexpression and Purification of Recombinant PfMetAP2
from E. coli and Yeast
The DNA sequence of the first seven amino acids 1MNKNNNK7 has high
similarity to 130KTKNNNN136, which prevented us from cloning the full-length
PfMetAP2. To circumvent the problem, the first five amino acids were skipped.
The gene encoding PfMetAP2 (D1-5) was amplified from genomic cDNA of
P. falciparum 3D7 strain. One pair of primers was used for cDNA amplification
(forward primer, 50-CGCGGATCCAATAAAGGTAGTGTTA-30; reverse primer,
50-CGCGAATTCTTAAAAGTCGGGACCACGAG-30). The PCR fragment was
cloned into pET28a and pYES2/NTc (same pair of restriction sites BamHI
and EcoRI). The DNA inserts in those two plasmids were confirmed by
sequencing prior to transformation into E. coli (BL21) and yeast (INVSc1)
according to the manufacturer’s instructions. The overexpression of
PfMetAP2(6-628) from E. coli (or yeast) was induced with 1 mM IPTG (or 2%
galactose plus 1% rafanose) at 16C for 3 days. The cells were suspended in
PBS (pH 7.5) and passed through a French press three times. Because both
recombinant proteins have 6xHis tag, they were further purified with cobalt-
based TALON affinity resin (Clontech) according to themanufacturer’s instruc-
tions. The identity of purified recombinant proteins was verified on western
blot analysis using anti-His-HRP antibody (Santa Cruz Biotechnology, Santa
Cruz, CA).
Biotin-Fum Affinity Binding Assay In Vitro
Recombinant PfMetAP2 from E. coli or yeast or recombinant HsMetAP2 (about
100 ng) was added to binding buffer (20 mM Tris-HCl [pH 7.1], 100 mM KCl,
0.2% Triton X-l 00, 20 mg/ml of leupeptin, aprotinin and 1 mg/ml of phenyl-200 Chemistry & Biology 16, 193–202, February 27, 2009 ª2009 Elsmethyl-sulfonyl fluoride). They were incubated for 2 hr with biotin or biotin-
Fum or ethanol at 4C. Following incubation, 20 ml streptavidin sepharose
(Pierce Biotech, Rockford, IL) was added and the mixture was incubated at
4C for another 2 hr. The beads were collected by centrifugation and washed
twice with 500 ml lysis buffer for 5 min. An aliquot of 40 ml of 13 SDS loading
buffer was added; the samples were then boiled for 10 min, loaded onto
a 12% SDS-PAGE gel, and subjected to western blot analysis. Proteins were
identified using anti-His-HRP antibody. For competition assay, the proteins
were first incubated with Fum-12O2-Dex4 or ethanol for 2 hr at 4C before
25 mM biotin-Fum was added for the rest of experiment as described above.
To determine whether the binding is covalent on near-western blot assay, as
reported previously (Griffith et al., 1997), 40 ml of 13 SDS loading buffer was
directly added to the proteins after the 2-hr incubation with biotin-Fum or
ethanol at 4C. After being boiled for 10 min, the samples were analyzed using
western blotting firstwith strep-HRP (GEHealthcare, Piscataway, NJ) (to check
the biotinylation) and then stripped, followed by blotting with anti-His-HRP
antibody (to check equal loading). Alternatively, the proteins after the 2-hr incu-
bation with biotin-Fum or ethanol were dialyzed against 2 l of binding buffer
overnight at 4C. The remaining biotin-Fum-MetAP2 complex was captured
by streptavidin sepharose beads. TheMetAP2 proteins captured on the beads
were detected with western blotting using anti-His-HRP antibody.
Establishment of a Mammalian Three-Hybrid System with
Fum-12O2-Dex4 and its Application in Fumarranol SAR Studies
The system is similar to the previously reported system (Chen et al., 2006), with
somemodifications. In brief, plasmid pVP16-PfMetAP2 and pM-rGRHBD(524-
796) were cotransfected into 293T cells using FuGENE6 (Roche Applied
Science, Indianapolis, IN) according to the manufacturer’s instructions. To
determine whether Fum-12O2-Dex4 could induce expression of the reporter
gene luciferase, 24 hr after cotransfection, the cells were incubated in a 24-
well plate with different concentrations of Fum-12O2-Dex4 for another 48 hr.
To determine the luciferase activity, cells in each well were washed three times
with PBS (pH 7.5), transferred to Eppendorf tubes, and lysed with report lysis
buffer (25 mM Tris [pH 7.8], 2 mM DTT, 2 mM CDTA, 10% glycerol, and 1%
Triton X-100). The lysate was subject to luciferase assay using bettle luceferin
(Promega, Madison, WI) in luciferase reaction buffer (20 mM Tricine [pH 7.8],
1.07 mM (MgCO3)4$Mg(OH)2$5H2O, 2.67 mM MgSO4, 0.1 mM EDTA,
33.3 mM DTT, 270 uM coenzyme A, 470 mM luciferin, and 530 mM ATP.) as
a substrate. Uponmixture, the instantaneously generated chemiluminescence
signal was determined by 1450 MicroBeta plate reader (Wallac, Waltham, MA)
using a preset program. The protein concentration of each lysate was also
determined using the Bradford assay (Bio-Rad, Hercules, CA). To compare
the relative luciferase activity of each sample, the readout of chemilumines-
cence signals were first divided by their corresponding protein concentrations
and then subtracted by background (no Fum-12O2-Dex4 treatment). The net
luciferase activity of each sample thus obtained was normalized against the
control to obtain the relative luciferase activity. To determine the ability of
different drugs to bind PfMetAP2, they were preincubated with the cotrans-
fected cells for 4 hr before the addition of 0.3 mM Fum-12O2-Dex4.
Antiproliferation Assay
P. falciparum NF54 (wild-type) and W2 strain (multidrug-resistant) were main-
tained at 37C in RPMI 1640 medium with 10% human serum at 3%–5%
hematocrit in a reduced oxygen environment produced by the candle-jar
technique (Trager and Jensen, 1976). Parasites were incubated with test
compounds for 24 hr followed by the [3H]-hypoxanthine (GE Healthcare, NJ)
incorporation assay described previously (Chen et al., 2006). Percentage of
control (no drug treatment) was used to determine IC50 values.
Animal Experiments
C57BL/6 mice (female, 4-6 wk old) were obtained from NCI and treated in
accordancewith Johns Hopkins Animal Care and Use Committee procedures.
Mice were infected with P. yoelli 17X lethal strain by intraperitoneal injection of
4 3 106 parasitized erythrocytes. Test compounds were administered subcu-
taneously starting 1 hr post infection once a day for 4 days. Control mice were
given vehicle only. Chloroquine and TNP-470 was used as positive control.
Blood was taken from the tail 24 hr after the last drug administration on day
4, and blood smears were prepared and stained with Giemsa. Parasitemiaevier Ltd All rights reserved
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erythrocytes per filed. Data were shown as mean percentage of parasitemia ±
SD. Mice that were alive on day 30 with no detectable parasitemia on slide
were considered cured.
Statistics
IC50 values for drug competition assay in three-hybrid system and cell prolifer-
ation assays were determined using four-parameter logarithmic analysis with
GraphPad Prism4 and are presented as the mean ± SD for triplicate experi-
ments. For animal tests, p values were determined using the two-tailed
Student’s t test.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
Supplemental References and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00030-1/.
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